An efficient epithelial-mesenchymal transition-related gene signature for predicting the survival of patients with lung adenocarcinoma.

IF 1.7 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2025-08-31 Epub Date: 2025-08-28 DOI:10.21037/tcr-2025-1455

Pengkai Han, Chittibabu Guda, Qiping Liu

{"title":"An efficient epithelial-mesenchymal transition-related gene signature for predicting the survival of patients with lung adenocarcinoma.","authors":"Pengkai Han, Chittibabu Guda, Qiping Liu","doi":"10.21037/tcr-2025-1455","DOIUrl":null,"url":null,"abstract":"Background: Epithelial-mesenchymal transition (EMT) plays an important role in the pathogenesis of lung adenocarcinoma (LUAD). In this study, we aimed to construct a prognostic signature based on EMT that could predict the prognosis of patients with LUAD.Methods: The messenger RNA (mRNA) expression profiles and the clinical data were downloaded from The Cancer Genome Atlas (TCGA) as the training set while data from the Gene Expression Omnibus (GEO) served as the validation set. Differentially expressed EMT-related genes (EMTGs) were identified from the training dataset. Univariate and multivariate Cox regression analyses were employed to develop a gene signature from the EMTGs to predict overall survival (OS) time. The prediction performance of the signature was tested using the time-dependent receiver operating characteristic (ROC) curve. The signature was verified in the TCGA dataset and the external dataset, GSE30219. A corresponding nomogram was also constructed to predict the prognosis of patients with LUAD. The expression of the prognostic genes at the protein level was investigated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. Gene set enrichment analysis was conducted to reveal the biological pathways associated with the high-risk group and the low-risk group.Results: A set of 79 differentially expressed EMTGs were identified. An EMT-related signature was constructed which classified patients with LUAD into two subgroups based on the median risk score. In the ROC curve analysis, the prognostic signature had a moderate discrimination accuracy for the 1-, 3-, and 5-year survival rate with areas under the curve (AUCs) of 0.732, 0.675, 0.702 in TCGA training set, respectively and 0.813, 0.672, 0.706 in the GSE30219 validation set, respectively. The established nomogram effectively predicted the OS of patients with LUAD.Conclusions: The novel EMT-related signature established in this study is a robust and independent prognostic indicator for patients with LUAD. This signature is expected to improve the personalized management of patients with LUAD.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4989-5001"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432770/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2025-1455","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Epithelial-mesenchymal transition (EMT) plays an important role in the pathogenesis of lung adenocarcinoma (LUAD). In this study, we aimed to construct a prognostic signature based on EMT that could predict the prognosis of patients with LUAD.

Methods: The messenger RNA (mRNA) expression profiles and the clinical data were downloaded from The Cancer Genome Atlas (TCGA) as the training set while data from the Gene Expression Omnibus (GEO) served as the validation set. Differentially expressed EMT-related genes (EMTGs) were identified from the training dataset. Univariate and multivariate Cox regression analyses were employed to develop a gene signature from the EMTGs to predict overall survival (OS) time. The prediction performance of the signature was tested using the time-dependent receiver operating characteristic (ROC) curve. The signature was verified in the TCGA dataset and the external dataset, GSE30219. A corresponding nomogram was also constructed to predict the prognosis of patients with LUAD. The expression of the prognostic genes at the protein level was investigated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. Gene set enrichment analysis was conducted to reveal the biological pathways associated with the high-risk group and the low-risk group.

Results: A set of 79 differentially expressed EMTGs were identified. An EMT-related signature was constructed which classified patients with LUAD into two subgroups based on the median risk score. In the ROC curve analysis, the prognostic signature had a moderate discrimination accuracy for the 1-, 3-, and 5-year survival rate with areas under the curve (AUCs) of 0.732, 0.675, 0.702 in TCGA training set, respectively and 0.813, 0.672, 0.706 in the GSE30219 validation set, respectively. The established nomogram effectively predicted the OS of patients with LUAD.

Conclusions: The novel EMT-related signature established in this study is a robust and independent prognostic indicator for patients with LUAD. This signature is expected to improve the personalized management of patients with LUAD.

Abstract Image

查看原文本刊更多论文

预测肺腺癌患者生存的有效上皮-间质转化相关基因标记。

背景：上皮-间质转化（Epithelial-mesenchymal transition， EMT）在肺腺癌（LUAD）的发病机制中起重要作用。在本研究中，我们旨在构建基于EMT的预后特征，以预测LUAD患者的预后。方法：从The Cancer Genome Atlas （TCGA）下载信使RNA （mRNA）表达谱和临床数据作为训练集，从Gene expression Omnibus （GEO）下载数据作为验证集。从训练数据集中鉴定出差异表达的emt相关基因（emtg）。采用单因素和多因素Cox回归分析从emtg中提取基因标记以预测总生存时间。采用随时间变化的受试者工作特征（ROC）曲线对信号的预测性能进行了测试。在TCGA数据集和外部数据集GSE30219中验证了该签名。并构建相应的nomogram来预测LUAD患者的预后。临床蛋白质组学肿瘤分析联盟（CPTAC）数据集研究了预后基因在蛋白质水平上的表达。通过基因集富集分析，揭示与高危组和低危组相关的生物学通路。结果：共鉴定出79个差异表达的emtg。构建emt相关特征，根据中位风险评分将LUAD患者分为两个亚组。在ROC曲线分析中，预后特征对1年、3年和5年生存率的判别准确率中等，TCGA训练集的曲线下面积（auc）分别为0.732、0.675、0.702，GSE30219验证集的auc分别为0.813、0.672、0.706。所建立的nomogram可有效预测LUAD患者的OS。结论：本研究建立的新的emt相关特征是LUAD患者可靠且独立的预后指标。这一签名有望改善LUAD患者的个性化管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.